GSK's Option Strategy For Human Genome Sciences' Lupus Drug Looking Smarter After BLISS-52 Win
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive data from one of two Phase III trials needed for a BLA raise hopes, stock prices for the two companies.
You may also be interested in...
Benlysta Back In The Spotlight With BLISS-76, But Second Phase III Still May Not Be Enough To Support Some Claims
BLISS-76 shows Benlysta 10 mg/kg is efficacious in patients with systemic lupus erythematosus; HGS/GSK expect to file in first half 2010.
Benlysta Back In The Spotlight With BLISS-76, But Second Phase III Still May Not Be Enough To Support Some Claims
BLISS-76 shows Benlysta 10 mg/kg is efficacious in patients with systemic lupus erythematosus; HGS/GSK expect to file in first half 2010.
Outlook BLISSful For HGS' Benlysta After Full Data Released At ACR
PHILADELPHIA - The full data set for Human Genome Sciences' pivotal BLISS-52 study - presented at the American College of Rheumatology meeting on Oct. 20 - gives some indication that the firm's systemic lupus erythematosus candidate Benlysta (belimumab) could have a broader than expected commercial reach